Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK

INTRODUCTION: A cost-effectiveness analysis was conducted comparing a fixed-ratio combination (FRC) of insulin glargine 100 units/mL plus lixisenatide (iGlarLixi) versus the FRC of insulin degludec plus liraglutide (iDegLira) and the free-combination comparators insulin glargine plus dulaglutide (iG...

Descripción completa

Detalles Bibliográficos
Autores principales: McCrimmon, Rory J., Falla, Edel, Sha, Jo Zhou, Alsaleh, Abdul Jabbar Omar, Lew, Elisheva, Hudson, Richard, Baxter, Mike, Palmer, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586275/
https://www.ncbi.nlm.nih.gov/pubmed/34714523
http://dx.doi.org/10.1007/s13300-021-01159-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586275/
https://www.ncbi.nlm.nih.gov/pubmed/34714523
http://dx.doi.org/10.1007/s13300-021-01159-y

Ejemplares similares